A Review of hormone-based therapies to treat adult acne vulgaris in women

M.K. Trivedi, BS, BA a,b,⁎, K. Shinkai, MD, PhD a, J.E. Murase, MD a,c

a Department of Dermatology, University of California San Francisco, San Francisco, CA
b University of Michigan Medical School, Ann Arbor, Michigan
c Department of Dermatology, Palo Alto Medical Foundation, Mountain View, CA

Abstract

Hormone-based therapies including combined oral contraceptive medications and spironolactone are considered effective therapies to treat adult acne in women. Our objective is to provide a concise and comprehensive overview of the types of hormonal therapy that are available to treat acne and comment on their efficacy and safety profiles for clinical practice. A systematic search using the PubMed Database was conducted to yield 36 relevant studies for inclusion in the review and several conclusions were drawn from the literature.

Treatment with oral contraceptive pills leads to significant reductions in lesion counts across all lesion types compared with placebo. There were no consistent differences in efficacy between the different combined oral contraceptive formulations. In terms of risk, oral contraceptive pill users had three-times increased odds of venous thromboembolism versus non-users according to a recent meta-analysis (95% confidence interval 2.46-2.59). Data on oral contraceptive pill use and breast cancer risk are conflicting but individual patient risk factors and histories should be discussed and considered when prescribing these medications. However, use of these medications does confer measurable protection from endometrial and ovarian cancer. Spironolactone was also shown to be an effective alternative treatment with good tolerability. Combined oral contraceptive medications and spironolactone as adjuvant and monotherapies are safe and effective to treat women with adult acne. However, appropriate clinical examinations, screening, and individual risk assessments particularly for venous thromboembolism risk must be conducted prior to initiating therapy.

© 2017 Women's Dermatologic Society. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Background

Acne in women over the age of 25 years, also known as adult-onset or persistent acne, affects approximately 12 to 22% of women in the United States. Historically, acne vulgaris has been primarily associated with the adolescent population. However, the burden of disease in the adult population has been highlighted in recent literature and women are noted to have greater incidence of disease compared with their male counterparts (Tanghetti et al., 2014). It should be noted that a number of adult women with acne may have underlying polycystic ovarian syndrome (PCOS) because approximately 70 to 80% of patients with PCOS suffer from cutaneous manifestations of the disease (Schmidt et al., 2015).

Adult acne in women is often associated with anxiety, depression, and a reduced quality of life (Tanghetti et al., 2014). Furthermore, this condition is characterized by high rates of treatment failure. In one prospective study of 200 women over the age of 25 years, approximately 80% of women failed multiple courses of systemic antibiotic medications and approximately 30% of patients relapsed after several therapeutic cycles of isotretinoin (Goulden et al., 1997). The high rates of treatment failure with traditional therapies along with more consciousness about antibiotic stewardship in dermatology patients, many of whom are on systemic antibiotic therapy for acne treatment, have motivated clinicians to reconsider the therapeutic targets of treatment in this population (Dreno et al., 2014).
There is considerable evidence on the role of sex hormones and specifically relative to androgen excess in the pathophysiology of acne vulgaris. For example, the development of acne in pre-pubertal girls has been correlated with high levels of dihydroepiandrosterone sulfate. Polycystic ovarian syndrome in which women experience hyperandrogenism is also associated with an increased prevalence of acne vulgaris. Individuals who are androgen insensitive do not experience acne. Most importantly and perhaps the strongest evidence is the effective use of combined oral contraceptive medications and anti-androgen therapies to treat women for acne. Hormonal therapy has been shown to be effective in postmenarchal adult women (age > 14 years) even in those women with normal androgen levels (Harper, 2008; Lolis et al., 2009; Lucky et al., 1991, 1994, 1997).

**Types of hormone therapies**

Hormone-based therapies can be separated into two broad categories: androgen synthesis inhibitors and androgen receptor antagonists. Estrogen and progesterone derivatives, which make up the components of COC medications, are generally considered androgen synthesis inhibitors. Commonly known androgen receptor antagonists include agents such as spironolactone, flutamide, cyproterone acetate, and progestins alone (Trifu et al., 2011). We will consider COC medications, spironolactone, and flutamide separately with regard to their use to treat patients with adult acne. We will briefly discuss the use of metformin although its use to treat adult acne is not formally reviewed in this paper.

**Combined oral contraceptive medications**

Oral contraceptive medications are thought to primarily exert anti-androgen effects through the actions of estrogen. Estrogen is known to stimulate the hepatic synthesis of sex hormone and bind globulin, which binds androgens and decreases levels of free testosterone, with dihydroepiandrosterone sulfate. Estrogen also inhibits 5-alpha reductase, which prevents the conversion of testosterone to the more potent dihydrotestosterone. Ovarian and adrenal androgen synthesis is also reduced due to the effects of estrogen and its negative feedback on gonadotropin, which releases hormone and leutinizing hormone (Haider and Shaw, 2004). Progestins have a lesser role in the production of anti-androgenic activity because early generation progestins have androgenic properties. When choosing oral contraceptive pills (OCPs) for the treatment of acne, third generation progestins (e.g., norgestimate or desogestrel) or later generations (e.g., fourth or fifth generation progestin-containing OCP formulations) are preferred because they have a lower androgenic activity overall. Progestins may contribute to the anti-androgenic properties of combined oral contraceptive medications through the reduction of gonadotropin-releasing hormone pulsatility and therefore luteinizing hormone production (Arowojolu et al., 2012).

Although numerous formulations of oral contraceptive medications exist, the U.S. Food and Drug Administration (FDA) has only approved three medications to date for the treatment of acne vulgaris: Ortho Tri-Cyclen (combination of norgestimate and ethinyl estradiol [EE]), Estrostep (combination of norethindrone acetate and EE), and Yaz (combination of drospirenone and EE; Ebede et al., 2009). A number of clinical trials on the safety and efficacy of different COC formulations to treat acne vulgaris have been published to date. Table 1 consolidates this evidence by COC formulation, duration of study, type of study, dosages used, and published results. To date, the superiority of particular OCP formulations for the treatment of acne have not been clearly demonstrated.

Multiple COC formulations have been studied in the context of treating adult women with acne vulgaris. All combinations that are reported in Table 1 exhibit some degree of efficacy in the reduction of acne lesion count. In terms of adverse events in patients with acne who were treated with COC medications, the most commonly reported events include headache, menstrual cycle irregularities, and emotional lability. Three of the studies reported severe adverse events related to COC use, with two cases of clinical depression and one case of ovarian cyst formation. However, the most common side effects that were reported in these studies are well known and expected for low-dose combined oral contraceptive medications. None of the studies reported above demonstrated any unexpected adverse events.

In terms of comparing efficacies, desogestrel may be slightly more effective than levonorgestrel COC formulations. However, one of the three comparison studies reported that the two have equal efficacy. The chloromadinone acetate (CMA) formulation may be more...
efficacious than levonorgestrel. However, CMA has not been marketed in the United States since 1972 after reports of mammary gland nodule formation in a study using canines. Several European countries, however, still use CMA COC formulations (Lingeman, 2012). All other comparison studies revealed results of non-inferiority. Studies that compared COC formulations head-to-head and had relevant results are listed in Table 2. A meta-analysis of 24 randomized trials that was conducted by Arowojolu et al., 2012 demonstrated no consistent differences in acne reduction between different combined OCPs (Arowojolu et al., 2012).

Counseling for patients: Risks, benefits, and contraindications

COC formulations can provide significant relief to patients who suffer from severe acne vulgaris, especially when conventional therapy has failed. However, to achieve maximum benefits and safety for each individual patient, counseling and discussion must be pursued during the initial visit. Contrary to previous practice, pelvic examinations and Pap smears are not required prior to prescribing COC medications according to recommendations by the World Health Organization, the American Congress of Obstetricians and Gynecologists (ACOG), and Planned Parenthood. This makes it more feasible for dermatologists to prescribe COC medications during routine clinic visits (Frangos et al., 2008). Patients commonly ask about cardiovascular, clotting, and cancer risks that are associated with oral contraceptive use. These issues are addressed separately below.

Cardiovascular risk

When counseling patients about cardiovascular risk, it is important to address modifiable risk factors such as smoking, hypertension, and diabetes and how control of these factors are the most important in reducing long-term risks of myocardial infarction and stroke. The risk of clotting should be discussed in context of baseline risks for women in the general population. The risk of deep vein thrombosis in women at baseline is 1/10,000 woman-years; at 1 year of COC use 3.4/10,000 woman-years; and during pregnancy 5 to 12/10,000. Peragallo Urrutia et al. (2013) conducted a meta-analysis of 14 different studies in which OCP users had three times increased odds for venous thromboembolism (VTE) compared with non-users.

Interestingly, older progestins seem to confer a lower VTE risk than newer progestin-based COC formulations. In 2012, drospirenone-based COC formulations were FDA-labeled with a warning for an increased risk of clotting (Lidegaard et al., 2012; Manzoli et al., 2012). However, this was contradicted when the results of a prospective controlled trial entitled “Long-term active surveillance study for oral contraceptives” were published in 2016 and demonstrated that drospirenone-based OCPs did not pose a higher risk for VTE compared with other OCPs (Dinger et al., 2016). In summary, there is a slightly increased risk of DVT in COC users but much less than that of the thrombophilic state of pregnancy.

Cancer risk

In 1996, the Collaborative Group on Hormonal Factors in Breast Cancer conducted a meta-analysis of 54 different epidemiological studies in which data from 53,297 women with breast cancer and 100,239 women without breast cancer was analyzed. The findings suggested a slightly increased risk of breast cancer in women who take a COC formulation (relative risk = 1.24, 95% confidence interval [CI]). This risk was increased up to 10 years after discontinuing birth control but did not extend past this time frame. Notably, women who were diagnosed with breast cancer and had taken COC medications had clinically less advanced tumors compared with women who were diagnosed with breast cancer and had not taken COC formulations (Collaborative Group on Hormonal Factors in Breast Cancer, 1996).

The more recent 2002 Women’s CARE study in which 4575 women were interviewed demonstrated contrary to the previously mentioned pooled analysis that there was no significant increase in the risk of breast cancer in COC users between the ages of 35 and 64 years (relative risk = 1.0). Similar to the pooled analysis study, the risk of breast cancer was not significantly related to the dose of estrogen or duration of COC use (Marchbanks et al., 2002). However, a 36-year follow-up in the Nurse’s Health Study, which aimed to assess the risk of breast cancer with COC use, reported a higher risk of premature deaths due to breast cancer in the population that used COC formulations ($p < .0001$). The authors hypothesized that this higher risk may be attributable to higher hormone doses that were used in earlier COC formulations (Charlton et al., 2014).

The risk of breast cancer with COC use is still controversial because these major studies have inconsistent outcomes. When discussing the risk with patients, it is important to highlight that the long-term risks remain unclear at this time. Newer formulations of OCPs use 5- to 10-fold less hormone than the original formulations so more data is needed to determine the true risk based on today’s available formulations. Providers should prescribe COC medications with an understanding of each patient’s unique history and other independent risk factors such as gene mutations, family history, age, and obesity.

It is also important to discuss the reduced overall risk of endometrial and ovarian cancer (Collaborative Group on Hormonal Factors in Breast Cancer, 1996; Frangos et al., 2008; George et al., 2008; Haider and Shaw, 2004). The follow-up on the Nurse’s Health Study mentioned earlier also reported a decrease in mortality rates from ovarian cancer in patients who used COC formulations ($p = .002$; Charlton et al., 2014). A 2008 meta-analysis of 45 different studies reported a significant correlation between duration of COC use and reduction in risk of ovarian cancer ($p < .0001$; Collaborative Group on Epidemiological Studies of Ovarian Cancer, 2008). The risk of endometrial cancer is also reduced, theoretically due to the suppression of endometrial growth through contraceptive cycle control. A 1999 Swedish case-control study noted that COC use decreased the risk of endometrial cancer by 30% and that this reduction was noticeable after 3 or more years of use (Weiderpass et al., 1999).

Other common risks and side effects

Other important questions include the risk of weight gain, common side effects, rare side effects, and use of OCPs with antibiotic medications. In 30% of patients, 1 kg to 2 kg of weight gain occur mostly due to fluid retention. Other common side effects include unscheduled bleeding, nausea, and breast tenderness. These symptoms except for unscheduled bleeding are lessened with decreased estrogen doses. Less common side effects include decreased libido, melasma, and mood changes (Junkins-Hopkins, 2010).

It is important to discuss the interactions of antibiotic medications with OCPs especially in women who utilize OCPs as their primary means of birth control. Since many antibiotic medications are inducers of 3A4, practitioners are concerned that OCP efficacy can be reduced with concurrent antibiotic medication use. However, according to the 2006 ACOG Practice Bulletin, pharmacokinetic evidence of reduced steroid levels with antibiotic medication use only exists for rifampin. Studies have failed to demonstrate similar findings for doxycycline, ampicillin, metronidazole, tetracycline, or quinolones (Kaunitz, 2006).
No severe AEs were reported in the study.

COC group experienced significantly greater reductions in noninflammatory and total acne count by week 24 compared with placebo ($p = .02$).

### Table 1
COC formulations, efficacy and safety reported in current literature

| Duration of Study | Dosage Studied | Type of Study | Efficacy Results | Safety Results |
|-------------------|----------------|---------------|------------------|---------------|
| **EE and DRSP (Yasmin)** | | | | |
| Efficacy and safety of 3 mg DRSP/20 mcg EE oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial (Koltun et al., 2008). | Six 28-day cycle treatments (approximately 6 months) | 3 mg DRSP/20 μg EE | Randomized double-blind placebo-controlled trial (sponsored study) | COC group had 4.31 odds of clear/almost clear skin as assessed by investigators after six 28-day cycles compared with placebo ($p = .001$) | COC group experienced three most common AEs: metrorrhagia, headache, and nausea at a higher rate compared with placebo. COC group experienced one serious AE: depression (not drug-related according to authors) |
| Treatment of moderate acne vulgaris using a COC formulation that contain EE 20 μg plus DRSP 3mg administered in a 24/4 regimen: A pooled analysis (Koltun et al., 2011). | Six 28-day cycle treatments (approximately 6 months) | 3 mg DRSP/20 μg EE | Pooled analysis of two large randomized placebo-controlled clinical trials (sponsored study) | Total, inflammatory, and non-inflammatory lesion counts were more greatly reduced for COC users vs. placebo by cycle 3 and at end point ($p < .0001$). COC group had approximately three times odds of clear/almost clear skin by endpoint compared with placebo by investigator assessment. | N/A |
| A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3 mg DRSP/0.02 mg EE compared with placebo in the treatment of moderate truncal acne vulgaris (Palli et al., 2013). | Six 28-day cycle treatments (approximately 6 months) | 3 mg DRSP/20 μg EE | Randomized double-blind parallel-group study | COC group experienced significantly greater reductions in noninflammatory and total acne count by week 24 compared with placebo ($p = .02$). | No severe AEs were reported in the study. |
| **EE and DSG (e.g., Desogen, Novial, Oilezz, Micrette)** | | | | |
| Effect of a DSG-containing oral contraceptive on the skin (Katz et al., 2000). | Six 28-day cycle treatments (approximately 6 months) | 50/100/150 μg DSG and 35/30/30 μg EE given in a 7/7/7-day regimen | Double-blind placebo controlled pilot study | COC group had significant reduction in sebum production on cheeks compared with placebo. No differences seen in acne lesion count between groups. Both patient and physician assessment of skin condition (VAS) significantly better in COC group. Patients experienced significant improvements in facial seborrhea. A total of 80% of the COC group had complete clearance of acne. | N/A |
| Effects of biphasic oral contraceptives containing DSG (Oilezz) on cycle control facial acne and seborrhea in healthy Thai women (Wonglikhitpanya and Taneeapanichkul, 2006). | Six 28-day cycle treatments (approximately 6 months) | N/A | Prospective, open, non-comparative, single center study | | No serious AEs reported |
| The effect of a phasic oral contraceptive containing DSG on seborrhea and acne (Kräcchin and Nap, 2006). | Four 28-day cycles (16 weeks) | 50/100/150 μg DSG and 35/30/30 μg EE given in a 7/7/7-day regimen | Non-randomized group-comparative trial (sponsored study) | COC users experienced statistically significant reduction in sebum production compared to controls. No difference in acne reduction. Both investigators and patients reported better skin condition in COC group (VAS). | Most common AE in COC group was headache and 26.1% of users experienced irregular bleeding during the first cycle. |
| **EE and LNG (e.g., Lybrel, Alesse, Tri-levlen)** | | | | |
| A randomized, controlled trial of a low-dose contraceptive containing 20 μg of EE and 100 mcg of levonorgestrel for acne treatment (Thiboutot et al., 2001). | Six 28-day cycles (approximately 6 months) | 20 μg of EE and 100 μg of LNG | Multicenter, randomized, double-blind placebo-controlled clinical trial | By cycle 6, inflammatory, non-inflammatory, and total lesion counts were significantly reduced in COC group compared with placebo ($p < .05$). Physician and patient assessments were also significantly better in COC group ($p = .016$, and $p < .05$). Total and inflammatory acne lesion count ($p < .05$) and biochemical androgenicity markers were improved in COC group compared with placebo. | Menorrhagia, metrorrhagia, menstrual disorder, and emotional lability was significantly higher in the COC group. One serious AE occurred in the COC group: depression (and hospitalization). |
| Efficacy of a low-dose oral contraceptive containing 20 μg of EE and 100 μg of LNG for the treatment of moderate acne: A randomized, placebo-controlled trial (Leyden et al., 2002). | Six 28-day cycles (approximately 6 months) | 20 μg of EE and 100 μg of LNG | Randomized, double-blind, placebo-controlled clinical trial (Investigator-initiated) | | N/A |

(continued on next page)
Table 1

| Study Duration | Study Type | Drug | Comparator | Comparator Dose | Comparator Outcome | Comparator Effect | Comparator Safety |
|----------------|------------|------|------------|-----------------|---------------------|-------------------|------------------|
| 6 months       | Open-label, single-center, phase IV trial | EE and CMA (e.g., Belara) | 0.03 mg and CMA 2 mg (Belara) | | | | |
| 6 months       | Prospective single-center, investigator-initiated | EE and NGM (e.g., Ortho Tri-Cyclen, Vivelle) | CMA, chlormadinone acetate; COC, combined oral contraceptive; DRSP, drosperinone; DSG, desogestrel; EE, ethinylestradiol; N/A, not applicable; LNG, levonorgestrel; NGM, norgestimate; VAS, visual analogue scale. | | | |

**Contraindications of combined oral contraceptive formulations**

Important contraindications to consider prior to the initiation of COC therapy include cardiovascular risk factors, severe hypertension, history of stroke, VTE or myocardial infarction, smoking combined with age >35 years, history of migraine with focal aura, history of migraine combined with age >35 years, current or past history of breast cancer or endometrial cancer, cholestasis jaundice of pregnancy (or jaundice with previous OCP use), diabetes with complications, hepatic neoplasias, abnormal liver function, hypersensitivity to OCPs, pregnancy, and major surgery with prolonged immobilization (Bonnema et al., 2010; Frangos et al., 2008).

**Spironolactone**

Spironolactone is an aldosterone antagonist that is often used as a diuretic and provides mortality benefit for patients with severe congestive heart failure. However, in higher doses, this agent also exhibits anti-androgen effects through inhibition of the cytochrome p450 system, inhibition of 5 alpha-reductase activity, and increase of hepatic synthesis of sex hormone-binding globulin (Armanini et al., 2016). Although not an FDA-approved medication for the treatment of acne, clinicians have often used this agent when there is inadequate acne control in patients who are already treated with a COC, have a contraindication to COC formulations, have coexisting hypertension, or their economic barriers prevent the purchase of other acne-controlling medications. The usual dosing of this medication is 50 to 200 mg/day. Contraindications to the use of spironolactone include renal insufficiency, hyperkalemia, pregnancy, or unevaluated abnormal uterine bleeding (Zaenglein et al., 2016).

There have been no randomized prospective placebo controlled trials on the efficacy of spironolactone in the treatment of adult-onset acne vulgaris. However, a few observational and retrospective analyses have been conducted in the last decade. These studies demonstrate excellent rates of efficacy for oral spironolactone to treat female adult patients with acne. The treatment doses ranged from 100 to 200 mg/day. Sato et al. (2006) conducted a study in which 139 Japanese patients were treated with a 20-week tapered regimen of oral spironolactone. A total of 64 female patients completed the study and there was a 100% response rate with approximately 50% of patients who had an excellent response. A total of 23 male patients were also initially included in the study but treatment was stopped after seven men developed gynecomastia (Sato et al., 2006).

Yemisci et al. (2005) performed a similar study and demonstrated an 85% response rate with significant improvements in acne for responders. In another study on the effects of treatment with topical spironolactone, 78 patients were enrolled in a randomized, double-blind, placebo controlled trial. The effects of 5% topical spironolactone on acne were mixed with a significant decrease in total acne lesion count but no difference in acne severity index between the two groups (Afzali et al., 2012). In conclusion, on the basis of initial studies, oral spironolactone demonstrates adequate levels of efficacy especially for patients with recalcitrant and/or severe forms of acne and those who have failed with COC therapy.

Spironolactone has also been studied in combination with other acne therapies including topical retinoids and COC formulations that contain drospirenone (Krunić et al., 2008; Lessner et al., 2014). Both studies demonstrated that combination treatment with these agents is both efficacious and well-tolerated. Although spironolactone has been considered generally safe, there are certain common side effects including menstrual irregularities, breast tenderness, fatigue, and...
Head-to-head comparison studies of COC formulations in acne treatment

| Duration of Study | Type of Study | Dosages Studied | Results |
|-------------------|---------------|-----------------|---------|
| **DSG and EE vs. LNG and EE** | 1 year | Randomized clinical trial | 30 μg EE, 0.15 mg progestin (either DSG or LNG) |
| **A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris (Rosen et al., 2003).** | 9 months | Randomized control trial | 30 μg EE, 0.15 mg progestin (either DSG or LNG) |
| **Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg EE (Winkler et al., 2004).** | Group-comparative, randomized, multicenter trial (sponsored study) | 20 μg EE/0.15 mg DSG vs. 20 μg EE/0.10 mg LNG |
| **DSG/EE vs CPAP/EE** | Six 28-day cycles (approximately 6 months) | Open, randomized, group-comparative, multicenter study | EE/DGN: days 1-7: 0.04 mg EE, 0.025 mg DGN; days 8-22: 0.03 mg EE, 0.125 mg DGN EE/NG: days 1-7: 0.035 mg EE, 0.18 mg NG; days 8-14: 0.035 mg EE, 0.215 mg NG; days 15-21: 0.035 mg EE, 0.25 mg NG. |
| **DSG/EE vs. NGM/EE** | 6 months | Investigator-blinded, randomized, parallel group phase III trial, multicenter (investigator-initiated) | EE/DSG: days 1-7: 0.04 mg EE, 0.025 mg DSG; days 8-22: 0.03 mg EE, 0.125 mg DSG EE/NGM: days 1-7: 0.035 mg EE, 0.18 mg NG; days 8-14: 0.035 mg EE, 0.215 mg NG; days 15-21: 0.035 mg EE, 0.25 mg NG. |
| **CMA/EE vs. LNG/EE** | Twelve 28-day cycles (approximately 1 year) | Single-blind, randomized, controlled, parallel phase III trial (sponsored study) | 0.03 mg EE/2 mg CMA vs. 0.03 mg EE/0.15 mg LNG |
| **CMA/EE vs. LNG/EE** | Nine 28-day cycles (approximately 9 months) | Multicenter, double-blind, randomized study | 30 μg EE/3 mg DSRP vs. 35 μg EE/2 mg CPA |
| **CMA/EE vs. LNG/EE** | Six 28-day cycles (approximately 6 months) | Multinational, multicenter, three-arm, double-blind and randomized trial (investigator-initiated) | 0.035 mg EE/2 mg CPA vs. 0.030 mg EE/2 mg LNG |
| **CMA/EE vs. LNG/EE** | 6 months | Randomized clinical trial (investigator-initiated) | 30 μg EE/3 mg DSRP vs. 30 μg EE/2 mg CMA |

Both acne and hirsutism were more significantly improved in the DSG/EE group vs. the LNG/EE group (p = 0.00). Weight gain was significantly greater in the LNG/EE group (p = 0.00). Mean acne lesion count was significantly reduced in both groups (p < 0.02). There was no statistically significant difference in acne lesion count reduction between the two groups (58.5% DSG vs. 52.8% LNG); limited power (5%). The DSG/EE group had fewer acne lesions compared to the LNG/EE group at the endpoint of six cycles of treatment (p < 0.05).

At the end of 6 months, no statistically significant differences were seen in acne lesion count reduction between the two groups. Percentage decreases in acne lesion count: EE/NNG: 74.4% vs. EE/DGN: 65.1%, p = .070

A greater percentage of CMA patients demonstrated at least a 50% reduction in papules and pustules by the 12th treatment cycle (59.4% vs. 45.9%, p = .02)

No significant differences in efficacy between CPA and DSRP formulations with both treatments achieving comparable lesion count reductions after nine cycles of treatment.

EE/DNG was shown to be superior to placebo and non-inferior to EE/CPA in reducing acne lesion count (p < .05).

Both groups demonstrated significant acne reduction from baseline (p < .01) by the end of study. The EE/DSRP response was better (faster and more prominent) at 3 months compared with the EE/CMA group (p < .05). The reduction in acne at 6 months was the same for both groups.

Acne resolution rates: Results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon: Worret et al., 2001)

Patients in both groups experienced statistically significant decreases in all acne lesion counts after cycle 3 and at the end of the 6-month study (p ≤ 0.003). There were no significant differences in acne reduction between the groups.

Percentage decreases in acne lesion count: EE/CMA: 74.4% vs. EE/DGN: 65.1%, p = .070

No significant differences in efficacy between CPA and DSRP formulations with both treatments achieving comparable lesion count reductions after nine cycles of treatment.

EE/DNG was shown to be superior to placebo and non-inferior to EE/CPA in reducing acne lesion count (p < .05).

Both groups demonstrated significant acne reduction from baseline (p < .01) by the end of study. The EE/DSRP response was better (faster and more prominent) at 3 months compared with the EE/CMA group (p < .05). The reduction in acne at 6 months was the same for both groups.

CMA, chloramadinone acetate; COC, combined oral contraceptive; CPA, cyproterone acetate; DSRP, drospirenone; DNG, desogestrel; EE, ethinylestradiol; LNG, levonorgestrel; NGM, norgestimate.

headache (Shaw and White, 2002). Hyperkalemia and the necessity of potassium level monitoring has been a subject of controversy in previous years. However, in 2015, Plovanich et al. published a landmark paper with the results of a retrospective analysis of hyperkalemia rates in women who were administered spironolactone from 2000 to 2014.
The researchers concluded that routine potassium monitoring in healthy women who take this medication is unnecessary. Healthy women were defined as women ages 18 to 45 years who were diagnosed with acne, with the exclusion of women with heart failure, on medication that affects the renin-angiotensin-aldosterone pathway, or who were diagnosed with renal disease (Plovanich et al., 2015). However, physicians should screen patients for bizarre diets that are high in potassium-containing substances such as coconut water prior to the initiation of spironolactone therapy.

Other safety considerations have included the effect of spironolactone on the body's thrombotic state. Unlike COC formulations, spironolactone seems to improve the thrombotic profile because aldosterone is known to be prothrombotic. Two individual case studies report the successful use of spironolactone-based treatment for Budd-Chiari syndrome in one patient with protein C deficiency and portal vein thrombosis in another patient with hepatitis B-related chronic liver disease (Hiroe et al., 2008; Kumar et al., 2011; Struthers and MacDonald, 2004).

At very high doses, spironolactone has also been associated with benign tumor formation in studies on animals. In a study on rats that were administered spironolactone at doses of 50, 150, and 500 mg/kg/day, increases in benign adenomas of the thyroid and testes were reported after 18 months. Similar doses in another study of rates led to the formation of hepatocellular adenomas in the subjects after 24 months, which caused the FDA to issue a black box warning (FDA, Aldactone Black Box Warning, revised 2008). However, long-term safety data does not support tumorigenic potential in humans (Danielson et al., 1982; Friedman and Ury, 1980; Shaw and White, 2002).

Flutamide

Flutamide is a selective androgen receptor antagonist, which is a well-known hormone-based chemotherapeutic agent to treat patients with prostate cancer. This agent has been purported as a potential therapy for adult onset acne vulgaris due to its antiandrogenic properties. However, very few studies on the efficacy of flutamide in acne treatment have been published thus far. A 2002 study conducted by Carmina and Lobo demonstrated the equal and significant efficacy of flutamide and a COC formulation (EE + cyproterone acetate) in the reduction of acne Cook scores in 48 hyperandrogenic women (Carmina and Lobo, 2002). However, the study did not directly assess the effects of flutamide in nonhyperandrogenic women who make up a significant portion of patients with adult acne. Paradisi et al. (2011) published a retrospective study on the effects of low dose flutamide in patients with acne who were over 15 years of age. More than 97% of patients reported satisfaction with the control of their acne on low-dose flutamide regimens over a 6-year period (Paradisi et al., 2011). However, flutamide has been used cautiously by clinicians because of potential hepatotoxic effects. In the previous study, 5% of patients experienced significant increases in transaminase levels. The androgen excess group of the American Society for Reproductive Medicine noted that flutamide had very limited value in the treatment of hyperandrogenism because of its hepatotoxic effects (Fauser et al., 2012).

Metformin

Interestingly, this well known drug that has been used to treat patients with diabetes for years, has recently gained attention as a potential treatment for hormonal acne in patients with polycystic ovarian syndrome (PCOS). Levels of facial sebum production are positively correlated with levels of the hormone insulin-like growth factor 1 (IGF-1), which is already known to be correlated with acne severity in women. IGF-1 is known to stimulate androgenic hormone production, which may explain this phenomenon (Vora et al., 2008). This finding is independent of a diagnosis of PCOS and suggests that targeting hyperinsulinemia and IGF-1—mediated metabolic changes may be potentially beneficial to patients outside of the PCOS population. Metformin has been shown to improve acne in several studies in patients with PCOS and hyperinsulinemia. It is thought to act by increasing insulin sensitivity and thereby reducing levels of IGF-1 and its downstream effects (Buhna, 2016).

Conclusion

Hormone therapy is a safe and effective option for women who suffer from adult acne. Most COC formulations demonstrate a certain level of efficacy in the treatment of patients with acne. Large meta-analyses that compared the different COC formulations do not demonstrate significant differences in efficacy between the formulations. Limitations of this review of current studies include difficulty to meaningfully compare the trials that are included because outcome measures varied across the studies. Lesion counts, sebum production, and investigator and patient-assessments were a few of the efficacy measures that were reported. Also, none of the trials that were reported were against active comparators. Most studies did not use follicle-stimulating and/or luteinizing hormone ratios or measurements of insulin resistance as exclusion criteria for screening. The most common side effects that were reported throughout the literature with the use of COC formulations included headache, menstrual irregularities, nausea, and breast tenderness, which are all common side effects that are expected with the use of low-dose COC formulations. Despite the relative safety of COC formulations, discussions on risks and side effects with individual patients is necessary to provide the safest and most beneficial care. Independent cardiovascular risk factors such as smoking, hypertension, and diabetes should be addressed. When discussing clotting risk, the increased risk of thrombophilia should be conveyed but contextualized because pregnancy confers a significantly higher risk of clotting. Although the FDA has issued warning labels for increased clotting risk with drospirenone-containing OCPs, a recent large prospective trial has shown that there is no increased clotting risk compared with other OCP formulations (Dinger et al., 2016). It is important to know the general risks, side effects, and contraindications of COC formulations prior to prescribing them as an acne treatment.

It is also important to inform patients that COC therapy improves acne over time. Most studies showed some improvement at 3 months of treatment and the greatest levels of improvement at 6 months. Oral spironolactone is a highly effective and safe option to treat patients with acne and contrary to prior practice potassium monitoring is not required in patients without a history of prior renal disease. Spironolactone may provide additional benefit in the treatment of patients with acne when used together with OCP. It is also a lower cost option for patients who cannot afford expensive oral isotretinoin therapy. Overall, anti-androgen therapy represents a safe and effective option for the treatment of patients with adult acne vulgaris and therapy should be prescribed on the basis of patient preference, cost, and individual patient characteristics because differences in effectiveness do not drastically vary from one formulation to another.

References

Afzali B, Yaghoobi E, Yaghoobi R, Bagherani N, Dabbagh M. Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: A randomized controlled trial. J Dermatolog Treat 2012;23:21–5.
Lello S, Primavera G, Colonna L, Vittori G, Guardianelli F, Sorge R, et al. Effects of two
Kumar M, Kamani L, Hussain R, Siddique S. Successful pregnancy outcome in decompen-
Koo EB, Petersen TD, Kimball AB. Meta-analysis comparing ef
Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a
Kerscher M, Reuther T, Bayrhammer J, Schramm G. Effects of an oral contraceptive
Carmina E, Lobo RA. A comparison of the relative ef
Bubna AK. Metformin - For the dermatologist. Indian J Pharmacol 2016;48:4
Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for
Armanini D, Andrisani A, Bordin L, Sabbadin C. Spironolactone in the treatment of
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal
Charlton BM, Rich-Edwards JW, Colditz GA, Missmer SA, Rosner BA, Hankinson SE,
Danielson DA, Jick H, Hunter JR, Stergachis A, Madsen S. Nonestrogenic drugs and
Kaunitz A. ACOG practice bulletin No. 73: Use of hormonal contraception in women
Sator PG, Schmidt JB, Hönigsmann H. Clinical evidence of the endocrinological in
Sato K, Matsumoto D, Iizuka F, Aiba-Kojima E, Watanabe-Ono A, Suga H, et al. Anti-
Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring under-
Paradisi R, Fabbri R, Porello E, Bartoli C, Seracchioli R, Venturoli S. Retrospective, study on the effects and tolerability of flutamide in a large population of patients with acne and seborrhea over a 15-year period. Gynecol Endocrinol 2011;27:823–9.
Paragolo L, Urrutia R, Cocytaux RR, McCorquon A, Giersch JM, Havleslyjuk J, Moorman PG, et al. Risk of acute thromboembolic events with oral contraceptive Use: A systematic review and meta-analysis. Obstet Gynecol 2013;122:380–9.
Plewig LV, Cunliffe WJ, Binder N, Höskén K. Effectiveness of an oral contraceptive containing 0.03 mg ethinylestradiol/2 mg desogestrel for the treatment of women with moderate acne: a randomized, double-blind, placebo-controlled trial. Obstet Gynecol 2009;80:25–33.
Plovnickich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol 2015;151:941–4.
Rosen MP, Breitkopf DM, Nagamanai M. A randomized controlled trial of second-versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol 2003;188:1158–60.
Sanam M, Ziba O. Desogestrel + ethinylestradiol versus levonorgestrel + ethinylestradiol. Which one has better affect on acne, hirsutism, and weight change. Saudi Med J 2011;32:23–6.
Sato K, Matsumoto D, Iizuka F, Aiba-Kojima E, Watanabe-Ono A, Suga H, et al. Anti-
Sato K, Matsumoto D, Iizuka F, Aiba-Kojima E, Watanabe-Ono A, Suga H, et al. Anti-
Sato K, Matsumoto D, Iizuka F, Aiba-Kojima E, Watanabe-Ono A, Suga H, et al. Anti-
Sato K, Matsumoto D, Iizuka F, Aiba-Kojima E, Watanabe-Ono A, Suga H, et al. Anti-
Sato K, Matsumoto D, Iizuka F, Aiba-Kojima E, Watanabe-Ono A, Suga H, et al. Anti-
Schlumberger GD, Leach SJ, Blaauw A, Bastian JM, Schipper P, Roodman GD. Antiangiogenic effects of a new oral contraceptive containing 300 μg of levonorgestrel and 100 μg of levonorgestrel for acne treatment. Fertil Steril 2001;76:461–8.
Thrif V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G. Cetorexone 17alpha-progesterone 15 cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot study. Dermatology 2003;206:241–8.
Schmidt TH, Kihanjuo K, Ceds M, Hudder L, Pasch L, Wang ET, et al. Cutaneous findings and systemic associations in women with polycystic ovary syndrome. Jama Dermatol 2015;94115:1.
Shaw JC, White LE. Long-term safety of spironolactone in acne: Results of an 8-year follow-up study. J Cutan Med Surg 2002;6:541–5.
Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004;61:663–70.
Tanghetti EA, Watkaw AK, Daniels SR, Yeomans K, Burk CT, Callender VD. Understanding the burden of adult female acne. J Clin Aesthet Dermatol 2014;7:20–30.
Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, double-blind, placebo-controlled trial of a low-dose contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment. Fertil Steril 2001;76:461–8.
Trif V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G. Cetorexone 17alpha-
Tartaglia M, de Gezelle H, Broekmeulen CJ. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care 2006;11:16–13.
Tartaglia M, de Gezelle H, Broekmeulen CJ. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care 2006;11:16–13.
van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of two combined oral contraceptives containing either cyproterone or cyproterone acetate on acne and seborrhea. Curr Med Res Opin 2002;69:2–15.
Vora S, Ovhal A, Jerajani H, Nair N, Chakraborty A. Correlation of facial sebum to serum insulin-like growth factor-1 in patients with acne. Br J Dermatol 2008;159:990–1.
Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131–7.

Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 (μg ethinylestradiol. Contraception 2004;69:469–76.

Wonglikhirpanya N, Taneepanichskul S. Effects of biphasic oral contraceptives containing desogestrel (Oleze) on cycle control facial acne and seborrhea in healthy Thai women. J Med Assoc Thai 2006;89:755–60.

Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: Results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001;203:38–44.

Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol 2005;19:163–6.

Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:945–973e33.